<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Neuropsychopharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Int. J. Neuropsychopharmacol</journal-id><journal-id journal-id-type="publisher-id">ijnp</journal-id><journal-title-group><journal-title>International Journal of Neuropsychopharmacology</journal-title></journal-title-group><issn pub-type="ppub">1461-1457</issn><issn pub-type="epub">1469-5111</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5616682</article-id><article-id pub-id-type="doi">10.1093/ijnp/pyw043.085</article-id><article-id pub-id-type="publisher-id">pyw043.085</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Sunday Abstracts</subject></subj-group></subj-group></article-categories><title-group><article-title>PS85. Efficacy and Safety of Generic Escitalopram (Lexacure) in Patients with Major Depressive Disorder: A 6-week, Multi-center, Randomized, Rater-blinded, Escitalopram-comparative, Non-inferiority Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jeong</surname><given-names>Jong-Hyun</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bahk</surname><given-names>Won-Myong</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Do Hoon</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Moon-Do</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Won</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Kwang Heun</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Kyung-Uk</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Woo</surname><given-names>Young Sup</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Jong-Chul</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>The Catholic University of Korea, Republic of Korea</aff><aff id="aff2">
<label>2</label>Hallym University, Republic of Korea</aff><aff id="aff3">
<label>3</label>Jeju National University, Republic of Korea</aff><aff id="aff4">
<label>4</label>Inje University, Republic of Korea</aff><aff id="aff5">
<label>5</label>Dongguk University, Republic of Korea</aff><aff id="aff6">
<label>6</label>Uijeongbu St. Mary's Hospital, Republic of Korea</aff><aff id="aff7">
<label>7</label>Chonbuk National University Hospital, Republic of Korea</aff><pub-date pub-type="collection"><month>6</month><year>2016</year></pub-date><pub-date pub-type="epub" iso-8601-date="2016-05-27"><day>27</day><month>5</month><year>2016</year></pub-date><volume>19</volume><issue>Suppl 1</issue><fpage seq="f">29</fpage><lpage>29</lpage><permissions><copyright-statement>&#x000a9; The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</copyright-statement><copyright-year>2016</copyright-year></permissions><self-uri xlink:href="pyw043.085.pdf"/><counts><page-count count="1"/></counts></article-meta></front><body><p>
<bold>Abstract</bold>
</p><p>
<bold>Objectives:</bold> The primary aim of this non-inferiority study was to investigate the clinical effectiveness and safety of generic escitalopram (Lexacure) versus branded escitalopram (Lexapro) for patients with major depressive disorder (MDD).</p><p>
<bold>Methods:</bold> The present study included 158 patients who were randomized (1:1) to receive a flexible dose of generic escitalopram (n = 78) or branded escitalopram (n = 80) over a 6-week single-blind treatment period. The clinical benefits in the two groups were evaluated using the MADRS), the 17-item HDRS, the CGI-S, and the CGI-I at baseline, Week 1, Week 2, Week 4, and Week 6. The frequency of adverse events (AEs) was also assessed to determine safety at each follow-up visit.</p><p>
<bold>Results:</bold> The MADRS, HDRS, CGI-S, and CGI-I scores significantly decreased in both groups, and there were no significant differences between the groups. At Week 6, 28 patients (57.1%) in the generic escitalopram group and 35 patients (67.3%) in the branded escitalopram group had responded to treatment (as indicated by a &#x02265;50% decrease from the baseline MADRS score; P = 0.126), and the remission rates (MADRS score: &#x02264;10) were 42.9% (n = 21) in generic escitalopram group and 53.8% (n = 28) in the branded escitalopram group (P = 0.135). The most frequently reported AEs were nausea (17.9%), sleepiness/somnolence (7.7%), weight gain (3.8%), and dry mouth (2.6%) in the generic escitalopram group and nausea (20.0%), sleepiness/somnolence (3.8%), weight gain (2.5%), and dry mouth (2.5%) in the branded escitalopram group.</p><p>
<bold>Conclusions:</bold> The present non-inferiority study demonstrated that generic escitalopram is a safe and effective initial treatment for patients with MDD and may also be considered as an additional therapeutic option for this population.</p></body></article>